- + 64% of revenues, €41.8m in net cash.
- 2016, a strategic turning point year, with major operational and business development investments made in anticipation of Median’s growth.
- Executive team strengthening through major company appointments with significant headcount increases in the US and in
- Development of iBiopsy®, the Median imaging phenotyping platform, is driving the R&D effort and is central in the company positioning strategy for upcoming years.
The Board of Directors of
“For Median Technologies, 2016 was a year of significant operational investments, particularly in the US and of major reinforcement of the group’s executive team with the appointment of new executive managers and directors. We considerably increased our headcounts both in the US and
Selected financial information (IFRS consolidated financial statements)
|In €K (audited figures)||2016||2015|
|Revenue from ordinary activities||6,369||3,890|
|Net financial result||68||156|
|Net Result – profit or (loss)||-9,111||-5,527|
2016: A year of significant investments to guarantee future growth
During the year,
Furthermore, the Group strengthened its R&D activities related to iBiopsy®, its imaging phenomics platform developed in collaboration with Microsoft. iBiopsy®, or Imaging Biomarker Phenotyping System, is an innovative imaging platform that combines non-invasive image biomarkers with phenomics. This unique combination of science and technology is at the core of precision and predictive medicine because it can provide insights into development of novel therapies and individualized treatment strategies. iBiopsy® can measure disease and treatment response without an invasive and costly biopsy.
Last November, Median appointed
Median also increased its investments in operational productivity tools and a customer relationship management platform (CRM) to help drive business development.
In 2016, the company’s average headcount totalled 84 compared to 57 in 2015. This headcount increase is reflected in the company’s staff costs. External costs increased in line with the growth in revenue and the costs linked to new order intake. Including these items, the Company reported an operating loss of €9,256k and net loss of €9,111k in line with the company’s expectations.
Outlook: Further expansion anticipated
Development of the iBiopsy® platform will continue and is at the core of the company’s R&D strategy. The first prototype of the platform was presented in the US at the Liver Meeting® and at the
The annual financial report is available on the company website: www.mediantechnologies.com
Our next update
Publication of the half-year results – 10
(*) Order backlog refers to customer orders that have been received but not yet invoiced. We have reinforced the accuracy of our backlog value to allow higher level of confidence in our forecasting and reporting. A new process of Recognition of Net New Business reportable to backlog ensures it is not subject to significant reversals or adjustment in the future and minimizes back outs through following new rules: Acceptable new wins are written by the customer certifying values, scope integrity and contingencies risk analysis.
(**) A project award is a notification announcing that the company’s solution has been selected for a specific project. This should result in a signed contract within 18 months, subject to upstream clinical results.
Founded in 2002, based in Sophia-Antipolis,
+33 4 92 90 65 82
Press – ALIZE RP
Caroline Carmagnol /
Investors – ACTIFIN